Hope and help for triple-negative (TNBC) and other forms of hormone-negative breast cancer.
Saturday, June 6, 2009
Your Best Way to Fight Breast Cancer: Lose Weight
Maintaining a healthy weight is crucial to avoiding breast cancer, fighting it once you’ve been diagnosed, and reducing its risk of recurrence. Yet most cancer patients are overweight and few know of the relationship between weight and cancer. Some stats:
• Women who gained 55 lbs. or more after age 18 had almost 1½ times the risk of breast cancer compared with those who maintained their weight, [July 12, 2006, issue of the Journal of the American Medical Association.]
• Many doctors reduce the levels of chemotherapy for obese women, potentially hurting their chances of survival, according to research at the University of Rochester Medical Center.
• Breast cancer survivors who ate a low-fat diet—of 32 grams a day, or roughly 20 percent of the daily allotment of fat— lowered their risk of recurrence, in some cases by an impressive 42 percent, according to the Women’s Intervention Nutrition Study (WINS).
• Canadian researchers discovered that breast cancer survivors, for the most part, have a surprisingly unhealthy lifestyle, being obese and low on physical activity. [June 1 2008 issue of Cancer, the journal of the American Cancer Society.]
• A majority of women in a recent study were unaware that being overweight increased their cancer risk. [October 2008, Obstetrics and Gynocology.]
Monday, June 1, 2009
New drug being tested for triple-negative breast cancer
• PARP inhibitors block the action of an enzyme that helps repair DNA. Without the ability to repair their DNA, tumor cells can die or more easily be killed by chemo.
• BS-201, was developed by BiPar Sciences that was acquired in April by Sanofi-Aventis. AstraZeneca is also developing PARP inhibitors.
Friday, May 22, 2009
African-American Women May Refuse Important Treatments for Triple Negative
One in four African American women with late stage breast cancer refused chemotherapy and radiation therapy, says research to be published in the July 1, 2009 issue of Cancer, a journal of the American Cancer Society.
Researchers reviewed stage III breast cancer data from 2000 to 2006 from an inner city hospital in Atlanta that serves a large African American population.
They identified 107 cases diagnosed, treated or both from 2000 to 2006. Roughly 87 percent of these cases were in African American women; 29 percent of all cases were triple negative.
• 20.5 percent of patients with stage III breast cancer refused chemotherapy.
• 26.3 percent who should have received chest radiation refused.
• There was no difference in marital status, religious background, or age of the patients who refused either chemotherapy or radiation compared with the patients who received recommended care.
Why did some women refuse care? Researchers aren’t sure why, but they speculate that a range of factors could be involved: socioeconomic and demographic factors, cultural beliefs, healthcare access, additional illnesses, and patient choice.
But here’s the neat part:
As a result of the study, researchers have implemented a community outreach program that includes a nurse practitioner and a social worker who follow all patients throughout their cancer treatments, ensuring that they get proper care. All women should have this sort of resource, but this is a good beginning.
Source: “Characteristics and treatment modalities for African American Women diagnosed with Stage III breast cancer.” Monica Rizzo, Mary Jo Lund, Marina Mosunjac, Harvey Bumpers, Leslie Holmes, Ruth O’ Regan, Otis W. Brawley, and Sheryl Gabram. CANCER; Published Online: May 22, 2009 (DOI: 10.1002/cncr.24334); Print Issue Date: July 1, 2009.
Risk factors for triple negative breast cancer
• be younger at diagnosis
• African American
• overweight and/or obese at diagnosis if premenopausal
The were less likely to breastfeed for long periods—more than four months—and were more likely to not breastfeed if they had at least three children.
The study consisted of 2280 women diagnosed with invasive breast cancer (stages I, II, or IIIA) between 1997 and 2000 and recruited primarily from the Kaiser Permanente Northern California Cancer Registry and the Utah Cancer Registry. They were between 18 and 70 years old and between 11 and 39 months post-diagnosis, free of recurrence, and with no history of other cancers in the five years prior to enrollment.
Tumor subtypes the used and the percentage in that group:
Luminal A: ER positive and/or PR positive, and Her2 negative (73.4%)
Luminal B: ER positive and/or PR positive, and Her2 positive (11.6%)
Triple negative: ER negative, PR negative, and Her2 negative (11.3%)
Her2-overexpressing: ER negative, PR negative, and Her2 positive (3.7%)
Luminal B cases were more likely to be younger at diagnosis and were less likely to consume alcohol or use hormone replacement therapy.
Her2-overexpressing cases were more likely to be younger at diagnosis, less likely to use hormone replacement therapy, and Hispanic or Asian.
Some other interesting stats:
•The majority of the whites (75.3%), Asians (71.4%), Hispanics (68.5%), other (68.5%), and African Americans (59.4%) had luminal A tumors.
• Her2-overexpressing tumors were least common among all races/ethnicities (whites 3.1%, African Americans 3.2%, Asians 6.4%, Hispanics 6.6%, other 5.5%).
• African Americans had the highest prevalence of the triple negative subtype (28.4%) compared with the other races/ethnicities (whites 10.5%, Asians 6.3%, Hispanics 10.7%, other 13.0%).
•African Americans (average age: 56.2) and Asians (average:54.8 years) were more likely to be diagnosed at a younger age.
•Whites were more likely to be diagnosed at an older age (59.8).
•, Asians (59.1%) were less likely to be post-menopausal than whites.
(75.6%), African Americans (71.4%), and other races/ethnicities (72.9%).
• A family history of breast cancer was more common among whites (22.6%) and other
races/ethnicities (24.1%), than among the other groups.
• African Americans and Hispanics had more biological children and were younger during their first pregnancy.
• Whites were more likely to have consumed alcohol while Asians were more likely to have never smoked.
• More whites had used HRT (76.2%).
• Fewer Asians (44.1%) had used oral contraceptives.
• African Americans were more obese at diagnosis.
The study was published in the May 2009 Breast Cancer Research, an open access journal. Download a PDF here. Or read the abstract.
SOURCE: Kwan, ML, Kushi, L, Weltzien,E, Maring, B, Kutner, S, Fulton, R, Lee, M,Ambrosone, C, Caan,B, “Epidemiology of breast cancer subtypes in two prospective cohort studies of
breast cancer survivors,” Breast Cancer Research, 2009, 11:R31.
Thursday, May 21, 2009
Bisphosphonate may benefit metastatic hormone negative breast cancers
New study planned for hormone-negative therapies
Aragon Pharmaceuticals has raised $8 million to discover and develop new therapeutics for the treatment of hormone-negative cancers, with an initial focus on prostate and breast cancer.
The company has been involved in recent discoveries that show that the biology of hormone-negative cancers can be overcome through the creation of a new class of nuclear receptor targeting drugs.
The company will focus on androgen and estrogen receptors.
Read the company's news release here.
Tuesday, May 19, 2009
DEAR1 gene could explain triple negative breast cancer
They studied tissues from tumors of 123 women whose breast cancer began between ages 25 and 49 and advanced to invasive disease. Of these, 56 percent had lost DEAR1 ((ductal epithelium-associated ring chromosome 1) expression. This correlated with a family history of breast cancer and with triple-negative disease.
The authors suggested that measurement of DEAR1 expression “could be an important marker to stratify early-onset breast cancer patients for increased vigilance in follow-up and adjuvant therapy.”
"The correlation with local recurrence is significant because so many young women have recurrences in the breast, and cancers that do recur tend to be more aggressive," said senior author Ann McNeill Killary, Ph.D., professor in M. D. Anderson's Department of Genetics. "Young age has been considered a risk factor for local recurrence and metastasis. It is important to understand the genetic mechanisms operating in early-onset breast cancer and to determine whether there is a way to identify young women who might be at a higher risk of recurrence."
Three Years Cancer Free
Monday, May 18, 2009
Standard chemotherapy more effective than capecitabine for older women
Capecitabine is taken orally.
Women 65 and older were randomly assigned to standard chemotherapy or capecitabine . Among the patients in the standard chemotherapy group, 133 chose cyclophosphamide/methotrexate/fluorouracil, 184 chose doxorubicin/cyclophosphamide and nine withdrew without choosing a treatment.
CMF was administered in standard doses for six cycles repeated every six weeks.
AC was administered in standard doses for four cycles repeated every three weeks.
Capecitabine was administered in two divided doses for 14 consecutive days every three weeks for six cycles.
Androgen receptors: a new category of triple negative breast cancer?
“I think we are seeing the birth of a new concept in breast cancer—the androgen-receptor-positive breast cancer,” says Jose Baselga, M.D., co-chair of the Impakt Breast Cancer Conference in Brussels, Belgium. “This is an important development in finding new targets that we can attack with new drugs in the future.”
Baselga was responding to research presented at the conference on the effects of androgens on chemotherapy. Patients who were triple negative breast and who also had androgen receptors tended to react less favorably to chemotherapy than those without the receptors.
This is more evidence of what doctors have been saying for some time: Cancer is many diseases. It is important to understand that triple-negative is also more than one disease. That explains why I was lucky enough to celebrate my third post-diagnosis year cancer-free, while my friend Karen had a recurrence. I suspect that, even though our diseases were in the same general category of hormone-negative, they were significantly different and I lucked out.
A clinical trials is now underway to target these receptors, with the hopes of using it for prognosis and the development of drug therapy.
The Impakt conference was sponsored by the European Society for Medical Oncology May 7-8, 2009.
Saturday, May 9, 2009
From Dr. Susan Love: "Is TNBC Getting a Bad Rap?"
Triple Negative Breast Cancer Isn’t Always Deadly
Research at the New York University School of Medicine demonstrates that a diagnosis of triple negative breast cancer (ER-, PR- and Her2-) is not always lethal. Researchers studied 145 triple negative tumors and found:
• About 23 percent were moderate or low-grade.
• 11 were low grade, 23 were moderate grade, and 111 were high grade.
• Of the low grade lesions, only one had spread to the lymph nodes.
• Of the medium grade lesions, five had spread.
• Of the high grade lesions, 37 had spread.
"Our preliminary results show that triple negative breast cancers are a heterogeneous group. Although many are high grade lesions, some are moderate or low grade demonstrating a lower rate of lymph node metastasis," said Cecilia Mercado, M.D., an author of the study.
The research was presented at the American Roentgen Ray Society annual meeting, April 14, 2008.
Source: " Does Histologic Grade Correlate with Nodal Status in Triple-Negative Breast Carcinoma? " Vieira, C. , Mercado, C., Guth, A., Moy, L.,Toth, H., Cangiarella, J. American Journal of Roentgeonology. 190:A17-A21. 2008.
Triple Negative Survivor Story: Josie Garcia
Every day we hear of survival stories that stretch as far as distant, war-torn countries. Closer to home, we hear the story of the immigrant, of those rooted in our impoverished neighborhoods, of those affected by the current recession.
Survival is an opportunity at the turn of every day. For the sound-minded, those opportunities rank upwards till reaching the most important meaning for us: life. A life-threatening opportunity is when life grabs hold of your soul and knocks your senses so straight you never realized there was more to life in the "most" way.
Welcome to my survival story, one that has become more common due to medical breakthroughs and outreach. I am a breast cancer survivor. Just before the summer of 2007, at the age of 39, and as a single Mom to a 2-year-old boy, I received a shocking diagnosis: Stage III, triple negative breast cancer, tumor range six to nine centimeters with three enlarged lymph nodes. Read more
Wednesday, April 29, 2009
Ixempra Research Offers Hope for Triple Negative Breast Cancer
Bristol-Myers Squibb Company presented research at the 2008 San Antonio Breast Cancer Symposium (SABCS) last December that offers some encouragement for women with triple negative breast cancer. The company studied Ixempra (ixabepilone) plus capecitabine compared to capectabine alone in clinical trials
• Of 443 patients with triple negative breast cancer, Ixempra plus capecitabine is the first combination regimen to demonstrate statistically significant progression-free-survival compared to capecitabine alone.
• Triple negative patients who received Ixempra and capecitabine had an overall response rate of 31 percent compared to 15 percent for patients who received capecitabine alone . The progression-free survival of the combination group was a median of 4.2 months compared to a median of 1.7 months for the capecitabine-treated group.
An article in Medical News Today quotes one of the researchers:
"Patients with advanced, triple negative breast cancer have limited treatment options and a poor prognosis," said Hope S. Rugo, M.D., Clinical Professor of Medicine and Director, Breast Oncology Clinical Trials Program, University of California San Francisco Helen Diller Family Comprehensive Cancer Center. "For this reason, it is important to explore the potential of other current and developmental therapies to discover more and effective treatment options for patients with this specific type of breast cancer."
Natural Intervention Helps Chemo
Spending two hours a week in nature watching birds, tending to plants or gardens, sitting by a window with a view of trees or a garden can cut the fatigue that is often associated with cancer treatment. This comes from research in the journal Cancer Nursing. Here's what I said about it in an article I wrote in Mamm on cancer anxiety:
Research published in 2003 in the journal Cancer Nursing suggests one way to overcome attention problems that’s as simple as, well, a walk in the park. Bernadine Cimprich, R.N., Ph.D., the study’s lead author, studied mental fatigue in a group of women with newly diagnosed breast cancer. They agreed to follow a structured program of “natural intervention,” spending two hours a week in nature—watching birds or trees, tending to plants or gardens. They were also instructed to give their full attention to their surroundings, rather than listening to an iPod or planning a work meeting. The women took standard cognitive tests before intervention began, after surgery, then three, six and twelve months afterward. As compared to patients treated without any nature therapy, participants showed better sustained recovery of their attention skills.
Cimprich, associate professor at the University of Michigan School of Nursing in Ann Arbor, says that the stress of dealing with breast cancer can lead to “attention fatigue,” and that nature therapy helps relax the parts of the brain that help to focus actively on tasks. Catherine Vincent, R.N., Ph.D., was diagnosed with breast cancer in 2003 while working on a postgraduate fellowship with Cimprich, so using natural intervention was a logical approach as she went on her daily walks. “I just inhaled the outdoors,” says Vincent, 59, assistant professor of maternal-child nursing at the University of Illinois at Chicago. Her cancer treatment—which included chemotherapy—went smoothly, which she attributes to the conscious rest she gave her brain. “I know part of it was really paying attention to what I needed,” she says. “Part of it was restoration through natural intervention.” Read more here.
Monday, April 27, 2009
How to Counter the Side Effects of Chemo
Such were the wonders of chemo that nobody told me about.
I learned a great deal on my own, so to spare you that charm, here are some of the side effects of the chemo I had—four rounds of dose-dense Adriamycin (Doxorubicin) and Cytoxan (cyclophosphamide) every two weeks—and some suggestions for how to deal with those effects. AC, as this regimen is called, is fairly common for hormone-negative cancers, including triple-negative, that have not spread to the lymph nodes.
Chemo, in general, kills fast-growing cells, which are often cancer cells. That’s the good side of those toxins being pumped into you. However, your body has other fast-growing cells that are also affected—in your hair, the lining of your mouth, and digestive tract. Killing these changes your body. And I was not prepared for most of that.
I went through chemo fine, for the most part, given that I was going through chemo. I kept active, ate healthy, and spent marvelous time with my friends and family. But, as with all other aspects of this lovely journey, I could have been better informed.Losing your hair. This chemo effect is the most understood and expected. My doctor told me it would happen in the third week of chemo and, sure enough, that’s when my hair literally began coming out in chunks. Some women prepare for this ahead of time by getting their head shaved before the hair falls out. I wanted to be normal and natural for as long as I could. So, one warm June day, my hair came out like dead grass in an abandoned lot, and I literally pulled the rest out. Yes, I pulled my hair out, and I will never be able to use that metaphor again. My husband shaved the rest.
Losing your hair is so emblematic of having cancer that the more you can address this head-on (no pun honestly intended), the better. Some women paint their heads; others have friends who also shave theirs in a gesture of solidarity. I just got a couple of pretty cool wigs and simply smiled when people complimented me on my new ‘do.
Whatever makes sense for you.
A friend did tell me that, because I am tall, I would look elegant in long scarves and could make a great fashion statement. I wanted to tell her to make her own damn fashion statement, but I know she was honesty trying to be supportive, so I said nothing. (I found, though, that I could not keep scarves on; they just kept sliding off my stupid bald head.)Changes in your mouth. I did not expect this in the least. Because the cells on the lining of my mouth were killed, I lost a good deal of my sense of taste, which is why those biscuits tasted like lard. My acupuncturist suggested buying some Japanese plum sauce, which has a tangy taste and sort of shook up what taste buds remained. (She also told me the other day that my tongue had looked like raw meat at the time. It did feel especially raw.) I also found that chocolate malts tasted quite good.
The bigger mouth problem, though, was mouth sores. Lots of them. Doctors call this oral mucositis and recommend a variety of things to help it, including “miracle” or “oncology” mouthwashes and antibiotics. I found an over-the-counter version that had hydrogen peroxide. Other than making me foam at the mouth like Cujo, it worked fine. I suspect that a good salt-water rinse would work as well.Digestive tract pokiness. One result of the loss of some of the cells in your digestive tract is that your digestion slows down. This is for sure the nastiest side effect of chemo, and no doctor has ever talked to me about it, but chemo patients talk about it all the time. Serious constipation. Serious. I took a natural laxative, Senna Plus, which worked OK. I often had to overdose, plus I also resorted to plain old-fashioned charmers like Milk of Magnesia. The Mayo Clinic offers some good information on laxatives here.
I started taking a green drink every morning, a healthy tonic I still take. Green drinks are generally high in fiber and rich in antioxidants and vitamins. So they’re good for getting your digestion going and fighting the cancer. Oprah’s medical guru, Dr. Oz (really, Oz?) has a recipe online for his green drink here.
I actually do two green drinks. In the morning, I have a powdered version that has spirulina, sea grass, organic greens, plus vitamins and minerals, like Barlean’s Green. In the evening, my husband makes me a fresh juice of carrots, kale, cabbage, and parsley, with apples and lemon for taste. Full of antioxidants and heavy on cancer-fighting cruciferous veggies.
The green drinks together, I think, helped move my digestion along.
I also found that I needed to increase the amount of magnesium I took, which is often a cause of constipation in folks without chemo, especially if they are taking calcium.
I learned to eat small meals on chemo days, usually bland things like soups and toast or crackers. I had plenty of liquids, and I went to the acupuncturist beforehand. I usually had mild nausea for about 24 hours after chemo, but nothing serious.
My sense of smell, which has always been acute, remained lively, so the smell of even bland things like mashed potatoes often turned me off. We resorted to eating as many fresh foods as we could, which is also a highly healthy way to go.
Three years later, I still think about those lardy biscuits. My taste buds got back into shape within a month or two of chemo. Now, the biscuits taste as they should—creamy, crunchy, and cheesy. I know, though, that behind all those goodies, there is lard. And that is one lesson of chemo I am choosing to ignore.
I will do the green drinks, I will eat healthy most of the time, and I will keep my weight down. Occasionally, though, I want a cheese biscuit or six, lard and all.
For more information, check out my book, Surviving Triple-Negative Breast Cancer. You can get a free signed copy just by donating $25 to this site. Click the Donate button on the right to donate through PayPal. You'll then get an email from me asking how you want your book signed and where you want it sent. Or you can buy the book directly without a donation. Thanks! And hugs.
Tuesday, April 21, 2009
Zometa: Not Proven for Hormone-Negative
Zometa (zoledronic acid) has been touted as a life-saving drug, based on research in the February New England Journal of Medicine. And it looks like the drug has serious potential—for women with hormone-positive disease. Some things for women with hormone-negative breast cancer, including triple negative, to consider:
• The women studied were all premenopausal who were hormone-positive and were given hormonal therapy—either tamoxifen or Arimidex—plus goserelin (Zoladex) to suppress ovarian function.
• None received adjuvant (after surgery) chemotherapy;
• The study found a 98 percent chance of survival in young women who were given ovarian suppression and hormone therapy drugs but did receive any chemotherapy.
So this could be great news for a narrow group of women. Unfortunately, this does not include those of us with hormone-negative disease.
The Dr. Susan Love Research Foundation has a great analysis of this.
Back to the drawing board, docs. Find us a cure.
(My thanks to the talented Deb Lattimore for sending me Dr. Love’s link. You can read about Deb’s fight against triple negative, and enjoy her excellent photography, here. )
Hidden Sources of Caffeine
Caffeine has been linked to hormone-negative breast cancer, including triple negative. And it can lurk unseen in your diet.
I have been having heart palpitations, so I immediately decided that either 1) the chemo had caused heart failure or 2) I have lung cancer, putting pressure on my heart. After an X-ray showed both lungs and heart normal, I decided to get a clue and start looking at my diet to see what I was doing to cause the palpitations. If I could not find an answer, I would go to the doctor, but I suspected I could take care of this by finding culprits in my diet.
I did.
I discovered caffeine all over the place, which is bad news, because I have been avoiding caffeine, as I noted in an earlier post. Caffeine has been linked to increased risk of hormone-negative breast cancer, including triple negative.
What I learned from honestly assessing my diet:
• I had been adding green tea to my morning smoothie, thinking I was adding a jolt of health. I was, but it also came with a jolt of caffeine. I often link green tea to herbal teas and assume it is caffeine-free. In fact, it has less caffeine than black tea and much less than coffee, but it still has caffeine. Thumpety.
• I had been making some nice, strong decaf coffee daily in my French press. That’s OK, right? Wrong. Decaf has less caffeine, but it is not caffeine free. Researchers at the University of Florida compared caffeine in decaf coffee and found that different brands had from 8.6 mg to 13.9 mg, compared to an average of 85 mg for caffeinated coffee. So, the super-strong stuff I was making—and I was making a good 16 ounces of it—no doubt had the caffeine of one or two cups of regular. Add that to the green tea caffeine and I was getting quite a start to my day. Thumpety thump.
• My beloved Diet Coke still hooks me, and when I fall off the wagon, I do a great job. Restaurants give you free refills, right? Sometimes I embarrass myself with the number of times my glass is refilled. There’s about 47 mg, of caffeine in an 12-ounce serving of Diet Coke. Heaven only knows how many I have at a simple lunch. Thumpety thump thump.
• Dark chocolate is considered by some a cancer fighter because of its high levels of antioxidants and phytochemicals. And it has plenty of caffeine: 31 mg in a 1.45 oz, bar. I used to have a tiny square as a treat after a meal. That gradually expanded to 3,4,5 squares. Thumpety thump thump thump.
So, I reminded myself that I am not a bonehead, that I am supposed to be eating healthy, and that I am supposed to know these things. I cut the hidden caffeine from my diet for three days and, guess, what? No palpitations.
I am frankly a bit embarrassed about this, but I am fairly sure I am not the only person who gets caught in the unhealthy caffeine trap. My heart told me to stop. That is way better than a cancer recurrence.
And searching my own diet was far cheaper, easier, and more successful than going in for heart tests.
Friday, April 10, 2009
Laughing at Triple Negative Breast Cancer
Trudy Runnels is a 44-year-old mother from Waxahachie, Texas. She has a rare form of metastatic breast cancer (triple- negative). It is not funny. Trudy is.
On a recent afternoon, at Cancer Treatment Centers of America, Runnels and a handful of other cancer patients gathered in a group therapy session. Together, their laughter became medicine.
After all, a funny story can do the most amazing things for a cancer patient, according to Dr. Gerald Ellison, a psychologist who leads the Centers' weekly humor therapy class.
"Laughter stimulates the immune system to produce cells that are very powerful in fighting cancer," Ellison explained. " There are many medical benefits to laughter." Read more here.
University of Alabama to Search for Triple Negative Therapy
Now, Komen for the Cure and the Triple Negative Breast Cancer Foundation have awarded $6.4 million to the University of Alabama at Birmingham to study the development of a drug to be used with chemotherapy to treating triple negative breast cancer.
Researchers will also study ways to predict the therapies that will be most effective against triple negative breast cancer.
More good news--evidence that this cancer has caught researchers' eye. Yea.